EUVIMEDEUVIMED entdecken
Crossref

In Brief: Widaplik — Another Three-Drug Combination for Hypertension

The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 101-102

DOI: 10.58347/tml.2026.1757d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic indapamide, for treatment of hypertension in adults. Telmisartan, amlodipine, and indapamide are also available alone and in various combinations for treatment of hypertension. Two three-drug combinations containing an ARB, amlodipine, and the thiazide diuretic hydrochlorothiazide (Exforge HCT and Tribenzor) have been available for years (see Table 1).

Schlagwörter

Stichwörter der Autor:innen

ACE inhibitorsARBsExforgeOlmesartanTekturnaTribenzorWidaplikadverse effectsaliskirenamlodipinediureticsdosageefficacyhydrochlorothiazidehypertension

Zitieren

APA

(2026). In Brief: Widaplik — Another Three-Drug Combination for Hypertension. The Medical Letter on Drugs and Therapeutics, 68(1757), 101-102. https://doi.org/10.58347/tml.2026.1757d

Vancouver

In Brief: Widaplik — Another Three-Drug Combination for Hypertension. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):101-102. doi:10.58347/tml.2026.1757d

BibTeX
@article{euvimed2026,
  title = {In Brief: Widaplik — Another Three-Drug Combination for Hypertension},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1757},
  pages = {101--102},
  doi = {10.58347/tml.2026.1757d}
}
Kostenlos starten →